The growing popularity of online weight-loss drug providers is increasing demand for hormone replacement therapy (HRT), once stigmatized but now sought by women struggling with menopause symptoms like weight gain. With limited access to traditional HRT care, many are turning to telemedicine platforms offering both HRT and GLP-1 drugs, such as Noom, Midi, and Hims & Hers.
The global HRT market is projected to reach $35 billion by 2030, fueled by rising awareness of menopause treatments and consumer demand for wellness solutions. Studies show combining HRT with GLP-1s (e.g., Ozempic) can boost weight loss by up to 30% compared to GLP-1s alone. However, experts warn about risks from compounded drugs and reduced in-person medical oversight.
Providers like telehealth companies are capitalizing on affordability and convenience but face criticism over potential gaps in patient care and profit-driven motives. Doctors caution that skipping routine exams could lead to missed health issues, even as more women embrace HRT. Meanwhile, GLP-1s’ popularity is waning amid concerns about long-term side effects.
Source: https://www.axios.com/2025/03/11/online-glp-1-sales-fuel-hormone-replacement-therapy